Thursday, May 3, 2018

08:30 - 08:45  Opening Address
Room: Confederation I - Level 4

08:45 - 10:15  PL01: Plenary Session 01 - Global Perspective on Trends in Mesothelioma
Track: Epidemiology
Chairs: Jim teWaterNaude, South Africa & Donna Maziak, Canada
Room: Confederation I - Level 4

08:45  PL01.01: Nordic Perspective
Gunnar Hillerdal, Karolinska Hospital, Sweden

09:00  PL01.02: North American Perspective
Paul Demers, Cancer Care Ontario, Canada

09:15  PL01.03: Oceanian Perspective
Matthew Soeberg, The University of Sydney, Australia

09:30  PL01.04: Peripheral Blood DNA Methylation as Potential Biomarker for Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects (Abstract ID: 632)
Giuseppe Matullo, Italian Institute for Genomic medicine and Department of Medical Sciences, Italy

09:40  PL01.05: Malignant Pleural Mesothelioma (MPM): A Surveillance, Epidemiology and End Results (SEER) Database Analysis (Abstract ID: 712)
Hala Aziz, National Cancer Institute, Egypt

09:50  PL01.06: Asbestos Disease Research in Former Soviet Union and Russia: Literature Comparisons with United Kingdom and Japan (Abstract ID: 749)
Oluf Røe, Norwegian University of Science and Technology, Norway

10:00  PL01.07: Childhood School Attendance Near an Asbestos Cement Plant and Adult Mesothelioma Risk (Abstract ID: 800)
Sofie Dalsgaard, Aalborg University, Denmark

10:10  PL01.08: Question & Answer Period
10:15 - 11:00  **Poster Viewing with Coffee**  
Room: Confederation II/III - Level 4

11:00 - 12:30  **MS01: Mini Symposium 01 - Patterns of Practice, a Global Perspective**  
Track: Nursing  
Chairs: Rayelle Richard, Canada & Melissa Culligan, United States  
Room: Confederation I - Level 4

11:00  **MS01.01**: North American Perspective: Highlighting the Role of the Mesothelioma Nurse in a Multidisciplinary Clinic  
Anastasia Bykova, University Health Network, Canada

11:15  **MS01.02**: UK Perspective: Lessons from the UK  
Liz Darlison, Mesothelioma UK, United Kingdom

11:30  **MS01.03**: A South African Perspective  
Phemelo Magabanyane, Asbestos Relief Trust, South Africa

11:45  **MS01.04**: A Nurse’s Expertise in the Conduct of Clinical Trials in Mesothelioma  
Buerkley Rose, University of Chicago, United States

12:00  **MS01.05**: Case-Based Discussion (Surgical / Non Surgical)  
Melissa Culligan, University of Maryland School of Medicine, United States

12:15  **MS01.06**: Question & Answer Period

11:00 - 12:30  **MS02: Mini Symposium 02 - Molecular Pathways and Diagnosis in MPM**  
Track: Pathology  
Chairs: Aliya Husain, United States, & Andrew Churg, Canada  
Room: Provinces I - Level 4

11:00  **MS02.01**: Grading of Mesothelioma  
Aliya Husain, University of Chicago, United States

11:15  **MS02.02**: Live Cell Imaging for the Diagnosis of Malignant Pleural Mesothelioma by Needle-Based Confocal Laser Endomicroscopy (nCLE) (Abstract ID: 832)  
Paul Baas, Netherlands Cancer Institute, Netherlands

11:25  **MS02.03**: MET Amplification Status and Expression in Malignant Mesothelioma (Abstract ID: 788)  
Eric Santoni-Rugiu, Rigshospitalet, Denmark
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Id</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35</td>
<td>MS02.04</td>
<td>The Role of EZH2 in the Proliferation, Migration, and Tumorigenicity of Malignant Mesothelioma (Abstract ID: 679)</td>
<td>Tohru Tsujimura, Hyogo College of Medicine, Japan</td>
</tr>
<tr>
<td>11:45</td>
<td>MS02.05</td>
<td>HEG1 is a New Immunohistochemical Marker for the Pathological Diagnosis of Malignant Mesothelioma (Abstract ID: 623)</td>
<td>Kenzo Hiroshima, Tokyo Women's Medical University, Japan</td>
</tr>
<tr>
<td>11:55</td>
<td>MS02.06</td>
<td>Molecular Pathways and Biomarkers in Diagnosis and Prognosis of MPM</td>
<td>Sanja Dacic, Pittsburg University Hospital, United States</td>
</tr>
<tr>
<td>12:10</td>
<td>MS02.07</td>
<td>Molecular Subtypes Characterization of Malignant Pleural Mesothelioma and Deconvolution Approach for Prognostic Assessment (Abstract ID: 600)</td>
<td>Yuna Blum, Ligue Nationale Contre Le Cancer, France</td>
</tr>
<tr>
<td>11:00</td>
<td>MS03.01</td>
<td>Preclinical Imaging</td>
<td>Roslyn Francis, University of Western Australia, Australia</td>
</tr>
<tr>
<td>11:15</td>
<td>MS03.02</td>
<td>Dynamic Enhancement of Malignant Pleural Mesothelioma with Computed Tomography (CT): A Prospective Clinical Trial (Abstract ID: 825)</td>
<td>Sharyn Katz, University of Pennsylvania Perelman School of Medicine, United States</td>
</tr>
<tr>
<td>11:25</td>
<td>MS03.03</td>
<td>Novel Descriptors for Clinical Staging of Malignant Pleural Mesothelioma (Abstract ID: 784)</td>
<td>Muzaffer Metintas, Eskisehir Osmangazi University, Turkey</td>
</tr>
<tr>
<td>11:35</td>
<td>MS03.04</td>
<td>Novel MRI Methodology for the Assessment of Tumour Volume in MPM (Abstract ID: 619)</td>
<td>Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom</td>
</tr>
<tr>
<td>11:45</td>
<td>MS03.05</td>
<td>Deep Learning Applied to the Segmentation of Malignant Pleural Mesothelioma Tumor on Computed Tomography Scans (Abstract ID: 655)</td>
<td>Eyjolfur Gudmundsson, University of Chicago, United States</td>
</tr>
</tbody>
</table>
11:55 MS03.06: CT Radiomics to Predict Outcome in Patients with Malignant Pleural Mesothelioma (Abstract ID: 741)
Isabelle Opitz, University Hospital Zürich, Switzerland

12:05 MS03.07: An Update on the Staging System for MPM
Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States

12:20 MS03.08: Discussant: The Evolving Role of Imaging for Mesothelioma
Sam Armato, University of Chicago, United States

12:30 - 13:45 Lunch Break
Room: Confederation II/III - Level 4

13:45 - 15:15 MS04: Mini Symposium 04 - Towards Personalized Systemic Therapy
Track: Medical Oncology
Chairs: Anna Nowak, Australia & Oluf Røe, Norway
Room: Confederation I - Level 4

13:45 MS04.01: Novel Targets, New Drugs, and New Combinations
Dean Fennell, University of Leicester & University Hospitals of Leicester NHS Trust, United Kingdom

14:00 MS04.02: Loss of BAP1 Function Leads to TRAIL Sensitivity in Malignant Mesothelioma (Abstract ID: 759)
Krishna Kolluri, University College London, United Kingdom

14:10 MS04.03: The Prediction of Resistance to Chemotherapy Using Somatic Copy Number Variation in Mesothelioma (PRiSM) Study: An Update (Abstract ID: 745)
Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom

14:20 MS04.04: Genomic Mechanisms Underpinning BAP1 Loss in Mesotheliomas from Patients Treated with the EZH2 Inhibitor Tazemetostat (Abstract ID: 647)
Dean Fennell, University of Leicester & Leicester University Hospitals, United Kingdom

14:30 MS04.05: PARP Inhibitors as Single Agent or with Temozolomide against Primary Mesothelioma Cell Lines with BAP1 Mutations (Abstract ID: 771)
Daniel Rathkey, National Institutes of Health, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:40</td>
<td>MS04.06: Expression of FGFRs and Evaluation of Efficacy of Different TKIs against FGFR1-4 in MPM (Abstract ID: 790)</td>
<td>Gregor Vlacic, University Clinic Golnik, Slovenia</td>
</tr>
<tr>
<td>14:50</td>
<td>MS04.07: Discussant</td>
<td>Arnaud Scherpereel, Hospital of the University of Lille, France</td>
</tr>
<tr>
<td>15:00</td>
<td>MS04.08: What Do We Know about Targeting Metabolism in Mesothelioma?</td>
<td>Luciano Mutti, University of Salford, United Kingdom</td>
</tr>
<tr>
<td>13:45</td>
<td>MS05.01: Assessing the Carcinogenic Potential of Asbestos and Asbestiform Fibres in MexTAg Mice (Abstract ID: 630)</td>
<td>Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia</td>
</tr>
<tr>
<td>13:55</td>
<td>MS05.02: Implication of ADAM10 Protease in Malignant Pleural Mesothelioma (Abstract ID: 519)</td>
<td>Marine Bellefroid, University of Liege, Belgium</td>
</tr>
<tr>
<td>14:05</td>
<td>MS05.03: TAZ Activation by NF2-Hippo Pathway Dysregulation Induces Cytokine Expression and Provides Growth Advantage to Mesothelioma (Abstract ID: 580)</td>
<td>Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan</td>
</tr>
<tr>
<td>14:15</td>
<td>MS05.04: Early Events during Asbestos-Driven Tumor Development (Abstract ID: 611)</td>
<td>Emanuela Felley-Bosco, University Hospital Zürich, Switzerland</td>
</tr>
<tr>
<td>14:25</td>
<td>MS05.05: Evaluation of RAN Gene using siRNA and CRISPR/CAS9 in Malignant Pleural Mesothelioma (Abstract ID: 621)</td>
<td>Irene Dell’Anno, University of Pisa, Italy</td>
</tr>
<tr>
<td>14:35</td>
<td>MS05.06: A Potential Therapeutic Strategy for Malignant Mesothelioma with Heparanase Inhibitors (Abstract ID: 673)</td>
<td>Moshe Lapidot, Brigham and Women's Hospital, United States</td>
</tr>
</tbody>
</table>
14:45  **MS05.07: Small Molecule Transcriptional Suppression of PRMT5 Induces Synthetic Lethality in MTAP-Negative Mesothelioma**  
(Abstract ID: 734)  
Sara Busacca, University of Leicester, United Kingdom

14:55  **MS05.08: Depletion of M2 Mesothelioma-Associated Macrophages May Decrease Mesothelioma Cell Stemness Leading to Lessened Tumorigenesis**  
(Abstract ID: 563)  
Licun Wu, Toronto General Hospital and Princess Margaret Cancer Centre, Canada

15:05  **MS05.09: Discussant**  
Steven Mutsaers, University of Western Australia, Australia

**13:45 - 15:15**  
**Mini Symposium 06 - Malignant Effusions**  
Track: Symptom Control / Palliative Care  
Chairs: Fraser Brims, Australia & Dan Sterman, United States  
Room: Provinces II - Level 4

13:45  **MS06.01: Debate: What is the Optimal Approach to Manage Malignant Pleural Effusions?**

**Medical Management is Best**  
Nick Maskell, University of Bristol, United Kingdom

**Surgical Management is Best**  
Marc De Perrot, Toronto General Hospital and Princess Margaret Cancer Center, Canada

14:15  **MS06.02: The Prevalence of Pleural Effusions at Presentation: A Prospective Cohort of 229 Patients with Malignant Pleural Mesothelioma**  
(Abstract ID: 549)  
Anna Bibby, University of Bristol, United Kingdom

14:25  **MS06.03: Is Pleural Infection Associated with Longer Survival in Mesothelioma? A Cohort Study Using Hospital Episode Statistics Data**  
(Abstract ID: 757)  
Anna Bibby, University of Bristol, United Kingdom

14:35  **MS06.04: Catheter Tract Metastatis in Mesothelioma Patients with Indwelling Pleural Catheters**  
(Abstract ID: 833)  
Michael Mitchell, The Ottawa Hospital, Canada
14:45  MS06.05: Diagnostic Value of Pleural Effusion Tumor Markers for Malignant Pleural Mesothelioma (Abstract ID: 751)  
Yasuhiro Hida, Hokkaido University Hospital, Japan

14:55  MS06.06: Question & Answer Period

15:15 - 16:00  Poster Viewing with Coffee  
Room: Confederation II/III - Level 4

16:00 - 17:30  PL02: Plenary Session 02 - Immunotherapy of Mesothelioma  
Track: Medical Oncology  
Chairs: Scott Laurie, Canada & Jeremy Steele, United Kingdom  
Room: Confederation I - Level 4

16:00  PL02.01: Characterization of PD-L1 Protein Expression in a Large Cohort of Malignant Pleural Mesothelioma (Abstract ID: 699)  
Assunta De Rienzo, Brigham and Women’s Hospital, United States

16:10  PL02.02: Pathological Predictors of Response to Immunotherapy in MPM  
Françoise Galateau-Sallé, Centre Léon Bérard, France

16:25  PL02.03: Second- or Third-Line Nivolumab vs. Nivo + Ipilimumab in Mesothelioma: Final Results of IFCT-1501 MAPS2 Randomized Phase 2 Trial (Abstract ID: 540)  
Arnaud Scherpereel, Hospital of the University of Lille, France

16:35  PL02.04: Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma: Final Results of a Phase II Study (INITIATE) (Abstract ID: 669)  
Paul Baas, Netherlands Cancer Institute, Netherlands

16:45  PL02.05: DREAM: A Phase 2 Trial of DuRvalumab with First-Line chemotherapy in Mesothelioma with a Safety Lead-In (Abstract ID: 536)  
Anna Nowak, University of Western Australia, Australia

16:55  PL02.06: Real-World Outcomes for Patients Treated with Pembrolizumab (Pembro) for Relapsed Malignant Pleural Mesothelioma (MPM) (Abstract ID: 796)  
Kenneth O’Byrne, Queensland University of Technology, Australia
17:05  PL02.07: Discussion: The Evolving Landscape of Immunotherapy Trials for Mesothelioma  
Arnaud Scherpereel, Hospital of the University of Lille, France

17:20  PL02.08: Question & Answer Period

17:30 - 18:30  Poster Mixer with Poster Discussions  
Room: Confederation II/III - Level 4
Friday, May 4, 2018

08:45 - 10:15  **PL03: Plenary Session 03 - Asbestos Control Perspectives: Before the Ban, the Ban, after the Ban**
Track: Patient Advocacy
Chairs: Paul Wheatley-Price, Canada & Sam Armato, United States
Room: Confederation I - Level 4

08:45  **PL03.01: Surviving and Dying with Canadian Asbestos Hidden in Our Lungs. A Belgian World Activist Speaks Out**
Eric Jonckheere, Belgian Asbestos Victims’ Association, Belgium

09:00  **PL03.02: Advocating for a Ban in Emerging Economies: The Colombian Experience**
Guillermo Villamizar, Fundclas, Colombia

09:15  **PL03.03: After the Asbestos Ban - the Australian Experience**
Peter Tighe, Australian Asbestos Safety and Eradication Agency, Australia

09:30  **PL03.04: It Really Does Matter: Encouraging Workers Diagnosed with Mesothelioma to Apply for Compensation Just Makes Sense (Abstract ID: 819)**
Liane Murphy, The Ottawa Hospital, Canada

09:40  **PL03.05: How We Achieved an Asbestos Ban in Canada - and Where We Need to Go from Here (Abstract ID: 777)**
Alec Farquhar, Ontario Office of the Worker Adviser, Canada

09:50  **PL03.06: Implementing a Ban**
Bob Blakely, Canada’s Building Trades Unions, Canada

10:05  **PL03.07: Question & Answer Period**

10:15 - 11:00  **Poster Viewing with Coffee**
Room: Confederation II/III - Level 4
11:00 - 12:30  MS07: Mini Symposium 07 - Translating Clinical Knowledge into Clinical Action
Track: Nursing
Chairs: Anastasia Bykova, Canada & Liz Darlison, United Kingdom
Room: Confederation I - Level 4

11:00  MS07.01: Medical Oncology Treatment Modalities and Case Study
Buerkley Rose, University of Chicago, United States

11:15  MS07.02: Radiation Oncology Treatment Modalities and Case Study
Erica Glass, Maryland Proton Treatment Center, United States

11:30  MS07.03: Surgical Treatment Modalities and Case Study
Melissa Culligan, University of Maryland School of Medicine, United States

11:45  MS07.04: Receiving a Diagnosis of MESothelioma (RADIO Meso): Improving the Patient Experience
(Abstract ID: 546 - Young Investigator Award Winner)
Bethany Taylor, The University of Sheffield, United Kingdom

11:55  MS07.05: A Collaborative Approach to a Successful Support Group for Mesothelioma Patients and Carers (Abstract ID: 718)
Lorraine Creech, Glenfield Hospital, United Kingdom

(Abstract ID: 766)
Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom

12:15  MS07.07: Question & Answer Period

11:00 - 12:30  MS08: Mini Symposium 08 - Radiation Oncology
Track: Radiation Oncology
Chairs: Robert MacRae, Canada & Andreas Rimner, United States
Room: Provinces I - Level 4

11:00  MS08.01: SYSTEMS-2: A Phase II Randomised Study of Radiotherapy Dose Escalation for Pain Control in Malignant Pleural Mesothelioma
(Abstract ID: 554)
Miranda Ashton, University of Glasgow, United Kingdom
11:10  MS08.02: Stereotactic Body Radiation Therapy as Salvage Therapy for Oligometastasised Pleural Mesothelioma after Multimodal Therapy (Abstract ID: 602)
Olivia Lauk, University Hospital Zürich, Switzerland

11:20  MS08.03: Radical/Salvage Approaches
Charles Simone, Maryland Proton Treatment Center, United States

11:35  MS08.04: Toxicities and Outcomes of Whole Pleural Intensity-Modulated Proton Therapy for Lung-Intact Malignant Pleural Mesothelioma (Abstract ID: 767)
Jason Molitoris, University of Maryland Medical Center, United States

11:45  MS08.05: An Investigation of Hybrid Planning with Multi Criteria Optimization for Mesothelioma (Abstract ID: 557)
Timothy Mitchell, Beatson West of Scotland Institute, United Kingdom

11:55  MS08.06: Understanding the Immune Response to Radiotherapy in a Dual Tumour Model of Mesothelioma (Abstract ID: 565)
Wesley Wilson, University of Western Australia, Australia

12:05  MS08.07: Palliative Radiation
Noelle O’Rourke, NHS Greater Glasgow and Clyde, United Kingdom

12:20  MS08.08: Question & Answer Period

11:00 - 12:30  MS09: Mini Symposium 09 - Peritoneal Mesothelioma - Current Status
Track: Surgery
Chairs: Richard Alexander, United States & Kiran Turaga, United States
Room: Provinces II - Level 4

11:00  MS09.01: Updates in Peritoneal Mesothelioma
Richard Alexander, University of Maryland Medical Center, United States

11:15  MS09.02: Surgery for Peritoneal Recurrences and Management of Peritoneal Ascites
Kiran Turaga, University of Chicago, United States

11:30  MS09.03: Novel Systemic Therapy Approaches
Licun Wu, Toronto General Hospital and Princess Margaret Cancer Centre, Canada
11:45  MS09.04: Early Outcomes from a Monthly International Peritoneal Mesothelioma Multi-Disciplinary Team Meeting in the UK and Ireland (Abstract ID: 747)
Andreas Brandl, Basingstoke and North Hampshire Hospitals, United Kingdom

11:55  MS09.05: BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma (Abstract ID: 684)
Raunak Shrestha, Vancouver Prostate Centre, Canada

12:05  MS09.06: A Comprehensive Prognostic Model for Malignant Peritoneal Mesothelioma: Interim Analysis of an International Collaboration (Abstract ID: 594 - Young Investigator Award Winner)
David Chapel, University of Chicago, United States

12:15  MS09.07: Question & Answer Period

11:00 - 12:30  MS10: Mini Symposium 10 - Biomarkers of MPM: Inflammation, Antigens, T Cells and More
Track: Basic Science
Chairs: Jan van Meerbeeck, Belgium & Jenette Creaney, Australia
Room: Les Saisons - Level 3

11:00  MS10.01: Serum miRNA Profiling of Malignant Pleural Mesothelioma and Early Diagnosis: A Massive Parallel Sequencing Approach (Abstract ID: 562 - Young Investigator Award Winner)
Elisabetta Casalone, Italian Institute for Genomic Medicine, Italy

11:10  MS10.02: Preliminary Results of the Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) Study (Abstract ID: 620)
Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom

11:20  MS10.03: Experimental Model of Human Malignant Mesothelioma in Athymic Mice for in vivo Evaluation of Therapy Using MIF/CD74 Inhibitor (Abstract ID: 616)
Veronique Serre-Beinier, University Hospitals and Medical University of Geneva, Switzerland

11:30  MS10.04: Time Course of Myeloid-Derived Suppressor Cells and M2 Macrophages in Murine Malignant Pleural Mesothelioma Microenvironment (Abstract ID: 590)
Mikihiro Kohno, Toronto General Research Institute, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
</table>
| 11:40  | **MS10.05**: Chrysotile-Induced Malignant Mesothelioma in Genetically Engineered Mouse Models (Abstract ID: 811)  
Yuwaraj Kadariya, Fox Chase Cancer Center, United States |
| 11:50  | **MS10.06**: Immunogenomic Determinants of Response to PD-1 Blockade in Malignant Pleural Mesothelioma (Abstract ID: 746)  
Hyun-Sung Lee, Baylor College of Medicine, United States |
| 12:00  | **MS10.07**: Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes (TILs) (Abstract ID: 639)  
Astero Klampatsa, University of Pennsylvania, United States |
| 12:10  | **MS10.08**: Identification of the Molecular Signature of Intratumor Tregs and of Tumor-Derived Immunosuppressive Signals (Abstract ID: 606)  
Stefano Biffo, Istituto Nazionale di Genetica Molecolare, Italy |
| 12:20  | **MS10.09**: Question & Answer Period |

**Lunch Break**  
*Room: Confederation II/III - Level 4*

**MS11: Mini Symposium 11 - Advocacy and Screening**  
*Track: Patient Advocacy*  
*Chairs: Christopher Lee, Canada & Eudice Goldberg, Canada*  
*Room: Confederation I - Level 4*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
</table>
| 13:45| **MS11.01**: Mesothelioma Advocacy in the 21st Century (Abstract ID: 729)  
Linda Reinstein, Asbestos Disease Awareness Organization, United States |
| 13:55| **MS11.02**: Meet the Experts: Evaluation of Speed Dating with Researchers on Action Mesothelioma Day in the UK (Abstract ID: 670)  
Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom |
| 14:05| **MS11.03**: Documentation of Asbestos Exposure in the Medical Records of Patients with Mesothelioma (Abstract ID: 523)  
Christopher Lee, BC Cancer Agency, Canada |
Kate Slaven, Papworth Hospital, United Kingdom

14:25  MS11.05: Discussant
Paul Wheatley-Price, The University of Ottawa, Canada

Track: Screening
Chairs: Demetris Patsios, Canada & Sjaak Burgers, Netherlands
Room: Confederation I - Level 4

14:35  MS11.06: Screening for Malignant Pleural Mesothelioma and Early Lung Cancer in Asbestos-Exposed Individuals (Abstract ID: 768)
Demetris Patsios, University Health Network, Canada

14:45  MS11.07: An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant Pleural Mesothelioma (Abstract ID: 567)
Kevin Lamote, University of Antwerp, Belgium

14:55  MS11.08: Headspace Analysis of Mesothelioma Cell Lines to Pinpoint in Vivo Breath Biomarkers (Abstract ID: 641)
Kevin Lamote, University of Antwerp, Belgium

15:05  MS11.09: Discussant
Jan van Meerbeeck, Ghent University Hospital, Belgium

13:45 - 15:15  MS12: Mini Symposium 12 - Radical Surgical Approaches
Track: Surgery
Chairs: Harvey Pass, United States & Donna Maziak, Canada
Room: Provinces I - Level 4

13:45  MS12.01: Progress in Surgical Procedures and Techniques
Isabelle Opitz, University Hospital Zürich, Switzerland

14:00  MS12.02: The Relationship between Cancer Surgery, Lymph Nodes, Immunotherapy and T Cells (Abstract ID: 703)
Jenette Creaney, University of Western Australia, Australia

14:10  MS12.03: Efficacy of Neoadjuvant Chemotherapy Followed by Resection in Pleural Mesothelioma with Positive Cervical Mediastinoscopy (Abstract ID: 700)
Sristi Sharma, University of Colorado, United States
14:20 MS12.04: Impact of Different Treatment Modalities on Survival in Malignant Pleural Mesothelioma: Results of Case Control Analysis (Abstract ID: 754)
Muzaffer Metintas, Eskisehir Osmangazi University, Turkey

14:30 MS12.05: Pleurectomy/Decortication and Intraoperative Intrapleural Hyperthermic Cisplatin Perfusion for Malignant Pleural Mesothelioma (Abstract ID: 582)
Kenichi Okubo, Tokyo Medical and Dental University, Japan

14:40 MS12.06: Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients: A French Single-Center Cohort (Abstract ID: 748)
François Montagne, Hospital of the University of Lille, France

Servet Bölükbas, Kliniken Essen-Mitte, Germany

15:00 MS12.08: Discussant
Loic Lang-Lazdunski, Lister Hospital, United Kingdom

13:45 - 15:15 MS13: Mini Symposium 13 - Immuno-Oncology PD-1 and Beyond
Track: Medical Oncology
Chairs: Arnaud Scherpereel, France & Quincy Chu, Canada
Room: Provinces II - Level 4

13:45 MS13.01: Overview of Early Trials / Data on Non-PD-1 Drugs
Anna Nowak, University of Western Australia, Australia

14:00 MS13.02: Overview of CAR-T Therapy for Meso
Andrew Haas, University of Pennsylvania Perelman School of Medicine, United States

14:15 MS13.03: Mesothelin-Targeted Immunotoxin LMB-100 Plus Anti-PD-1 Antibody in Syngeneic Mouse Model Expressing Human Mesothelin (Abstract ID: 763)
Raffit Hassan, National Cancer Institute, United States

Evan Alley, University of Pennsylvania, United States
14:35  MS13.05: Rearrangement-Related Peptides with Neoantigenic Potential in Malignant Pleural Mesothelioma (Abstract ID: 533)
Aaron Mansfield, Mayo Clinic, United States

14:45  MS13.06: Rational Therapeutic Modulation of the Tumor Microenvironment Sensitizes Cancers to Immune Checkpoint Blockade (Abstract ID: 558 - Young Investigator Award Winner)
Rachael Zemek, University of Western Australia, Australia

14:55  MS13.07: PD1 Checkpoint Blockade Overcomes Upregulation of Multiple Inhibitory Receptors (Abstract ID: 724)
Jordan Dozier, Memorial Sloan Kettering, United States

15:05  MS13.08: Question & Answer Period

13:45 - 15:15 MS14: Mini Symposium 14 - The Roles of miRNA and BAP1
Track: Basic Science
Chairs: Michele Carbone, United States & Penelope Bradbury, Canada
Room: Les Saisons - Level 3

13:45  MS14.01: Elucidating BAP1-microRNA Regulatory Networks in Mesothelioma (Abstract ID: 544)
Judy Coulson, University of Liverpool, United Kingdom

Victor Martinez, BC Cancer Agency, Canada

14:05  MS14.03: Role of miRNA in Mesothelioma Progression
Michaela Kirschner, University Hospital Zurich, Switzerland

14:20  MS14.04: Histopathological and Molecular Characterization of BAP1 in Malignant Pleural Mesothelioma (Abstract ID: 584)
Assunta De Rienzo, Brigham and Women's Hospital, United States

14:30  MS14.06: Discovering and Translating BAP1 Dependencies: Towards Precision Therapy of Mesothelioma (Abstract ID: 740)
Sarah Taylor, University of Liverpool, United Kingdom

Michele Carbone, University of Hawaii Cancer Center, United States

14:50  MS14.08: Question & Answer Period
15:15 - 16:00 Poster Viewing with Coffee
Room: Confederation II/III - Level 4

16:00 - 17:30 PL04: Plenary Session 04 - The Genome and Epigenetics of Mesothelioma
Track: Basic Science
Chairs: Marie-Claude Jaurand, France & Christina Addison, Canada
Room: Confederation I - Level 4

16:00 PL04.01: Molecular Heterogeneity of Mesothelioma
Jean Didier, INSERM, France

Marc Ladanyi, Memorial Sloan Kettering Cancer Center, United States

16:30 PL04.03: The MexTAg Collaborative Cross: Identifying the Genetic Basis of Mesothelioma. An Interim Report (Abstract ID: 627)
Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia

16:40 PL04.04: Both Long-Fibre Carbon Nanotubes and Asbestos Alter the Level of DNA Methylation in the Pleura of Exposed Mice (Abstract ID: 761)
Joaquin Zacarias-Cabeza, Medical Research Council (MRC), United Kingdom

16:50 PL04.05: Long-Fibre CNT and Asbestos Induce Pleural Mesothelioma: A Key Role for Epigenetic Mechanisms in Disease Development (Abstract ID: 826)
Marion MacFarlane, MRC Toxicology Unit, United Kingdom

17:00 PL04.06: Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma (Abstract ID: 721)
Irma Dianzani, HUGEF Human Genetics Foundation, Italy

17:10 PL04.07: Question & Answer Period

17:15 PL04.08: Application of CGH in Mesothelioma and its Role in the Identification of New Treatment Targets
Michele Carbone, University of Hawaii Cancer Center, United States

17:30 - 18:30 Poster Mixer with Poster Discussions
Room: Confederation II/III - Level 4
Saturday, May 5, 2018

08:45 - 10:15  PL05: Plenary Session 05 - Multidisciplinary Management
Track: Surgery
Chairs: Paul Baas, Netherlands & Walter Weder, Switzerland
Room: Confederation I - Level 4

08:45  PL05.01: The Role of Surgery in the Multidisciplinary Management of Mesothelioma in 2018
Harvey Pass, New York University, United States

09:00  PL05.02: EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
(Abstract ID: 543 - Young Investigator Award Winner)
Jo Raskin, Antwerp University Hospital, Belgium

09:10  PL05.03: Does the Administration of Total Parenteral Nutrition Following Extended Pleurectomy Decortication Offer Any Benefit?
(Abstract ID: 663)
Alan Dawson, Glenfield Hospital, United Kingdom

09:20  PL05.04: Quality of Life is Not Deteriorated After (Extended) Pleurectomy/Decortication vs. Pneumonectomy in Mesothelioma Patients (Abstract ID: 589)
Olivia Lauk, University Hospital Zürich, Switzerland

09:30  PL05.05: Debate: When is the Best Time to Administer RT?

Pre-Op
John Cho, University Health Network, Canada

Post-Op
Andreas Rimner, Memorial Sloan Kettering, United States

09:55  PL05.06: Outcomes for Patients Treated with Surgery for Mesothelioma After Radiation Therapy: SMART Study Interim Results
(Abstract ID: 660)
John Cho, University Health Network, Canada

10:05  PL05.07: Question & Answer Period

10:15 - 11:00  Poster Viewing with Coffee
Room: Confederation II/III - Level 4
11:00 - 12:30  MS15: Mini Symposium 15 - Surgical Palliation
Track: Surgery
Chairs: Joe Friedberg, United States & Marc De Perrot, Canada
Room: Confederation I - Level 4

11:00  MS15.01: Diagnosis & Management of Local Recurrence
Raphael Bueno, Brigham and Women’s Hospital, United States

11:15  MS15.02: Is There a Role for Purely Palliative Surgery?
David Waller, St. Bartholomew Hospital, United Kingdom

11:30  MS15.03: Surgical Management of Malignant Pleural Mesothelioma After Induction Chemotherapy: 18 Years of Single Center Experience (Abstract ID: 592)
Olivia Lauk, University Hospital Zürich, Switzerland

11:40  MS15.04: Pleurectomy/Decortication, Intrapleural Betadine, Prophylactic Radiotherapy and Systemic Chemotherapy: Long-Term Results (Abstract ID: 706)
Loic Lang-Lazdunski, BUPA Cromwell Hospital, United Kingdom

11:50  MS15.05: The Transition of Quality of Life After Pleurectomy/Decortication for Malignant Pleural Mesothelioma (Abstract ID: 717)
Toru Nakamichi, Hyogo College of Medicine, Japan

12:00  MS15.06: The Improving Results of Trimodality Treatment Strategy for Operable Malignant Pleural Mesothelioma (Abstract ID: 552)
Kazunori Okabe, Yamaguchi Ube Medical Center, Japan

12:10  MS15.07: Feasibility of Intrapleural PDT Combined with Pleurectomy/Decortication Then Chemotherapy in Malignant Pleural Mesothelioma (Abstract ID: 593)
Arnaud Scherpereel, Hospital of the University of Lille, France

12:20  MS15.08: Question & Answer Period

11:00 - 12:30  MS16: Mini Symposium 16 - Interdisciplinary Symptom Control in MPM
Track: Symptom Control / Palliative Care
Chairs: Monica Malec, United States & Camille Munro, Canada
Room: Provinces I - Level 4

11:00  MS16.01: Psychological Aspects of Management Dyspnea
Amy Siston, University of Chicago, United States
11:15  **MS16.02: Case-Based Complex Pain Issues in MPM**  
Monica Malec, University of Chicago, United States

11:30  **MS16.03: A Multicentre RCT Assessing Regular Early Specialist Palliative Care in Malignant Pleural Mesothelioma: RESPECT-MESO**  
(Abstract ID: 676)  
Fraser Brims, Sir Charles Gairdner Hospital, Australia

11:40  **MS16.04: MesoTRAP: A Feasibility Study Comparing VAT Pleurectomy with IPC for Trapped Lung in Pleural Mesothelioma**  
(Abstract ID: 713)  
Robert Rintoul, University of Cambridge, United Kingdom

11:50  **MS16.05: MARS 2 Qualitative Assessment Study: Implications of Findings for Post-Surgical Follow-Up Care**  
(Abstract ID: 638)  
Angela Tod, The University of Sheffield, United Kingdom

12:00  **MS16.06: A UK General Hospital's Experience with Malignant Pleural Mesothelioma in a High-Incidence Area**  
(Abstract ID: 601)  
Lewis Standing, Northumbria Healthcare Trust, United Kingdom

12:10  **MS16.07: Question & Answer Period**

**11:00 - 12:30 MS17: Mini Symposium 17 - Benign vs. Malignant Mesothelial Proliferations and Subtypes of MPM**  
Track: Pathology  
Chairs: Andrew Churg, Canada & Françoise Galateau-Sallé, France  
Room: Provinces II - Level 4

11:00  **MS17.01: A Multi-Institutional Evaluation of Pleural Biphasic Mesothelioma by the International Mesothelioma Panel: New Insights**  
(Abstract ID: 774)  
Françoise Galateau-Sallé, Centre Leon Berard, France

11:10  **MS17.02: New Data of the Molecular Subtypes of Mesothelioma**  
Lynnette Fernandez-Cuesta, International Agency for Research on Cancer, France

11:25  **MS17.03: Differential Diagnosis of Malignant Pleural Mesothelioma: Effectiveness of a Gene Expression Panel on Pleural Effusions**  
(Abstract ID: 607)  
Rossella Bruno, University of Pisa, Italy
11:35  MS17.04: Image-Guided Percutaneous Pleural Biopsy Diagnostic Yield and Accuracy for Benign and Malignant Pleural Lesions (Abstract ID: 831)
Joao Inacio, The University of Ottawa, Canada

11:45  MS17.05: Immunohistochemical Detection of MTAP or BAP1 Protein Loss in Tissues and Cell Blocks for Diagnosis of Mesothelioma (Abstract ID: 709)
Kazuki Nabeshima, Fukuoka University School of Medicine, Japan

11:55  MS17.06: Gene Expression Profiling vs. p16 and BAP1 Evaluation in the Differential Diagnosis of Mesothelial Proliferations (Abstract ID: 609)
Greta Ali, Azienda Ospedaliero Universitaria, Italy

12:05  MS17.07: Correlation Between Benign and Malignant Mesothelial Proliferation
Andrew Churg, Vancouver General Hospital, Canada

12:20  MS17.08: Question & Answer Period

12:30 - 14:00  Lunch Break
Room: Confederation II/III - Level 4

14:00 - 15:30  PL06: Plenary Session 06 - Immunotherapy, Bench to Bedside
Track: Basic Science
Chairs: Penelope Bradbury, Canada & Luciano Mutti, United Kingdom
Room: Confederation I - Level 4

14:00  PL06.01: How Recent Insights into the Immune Environment in Mesothelioma are Informing the Next Generation of Immunotherapies
Jenette Creaney, University of Western Australia, Australia

14:15  PL06.02: Epigenetics for Immunotherapy: Application to Mesothelioma
Christophe Blanquart, CRCINA, France

14:30  PL06.03: Neoantigen Abundance and MHC Protein Expression Underlie Immunogenicity in Malignant Pleural Mesothelioma (Abstract ID: 785)
Hyun-Sung Lee, Baylor College of Medicine, United States
14:40  PL06.04: A Modified Measles Virus Exhibits Enhanced Oncolytic and Immunotherapeutic Properties Against Human Mesothelioma Cells (Abstract ID: 651)
Nicolas Boisgerault, CRCINA Cancer Research Center, France

14:50  PL06.05: Genetic Blockade of the Protein Tyrosine Phosphatase SHP1 Augments CAR T-Cell Activity against PDL1-Expressing Solid Tumors (Abstract ID: 526)
Edmund Moon, University of Pennsylvania Perelman School of Medicine, United States

15:00  PL06.06: Immune Profiling Identifies Differential Expression of Complement Pathway Genes Related to Molecular Clusters of Mesothelioma (Abstract ID: 586)
David Severson, Brigham and Women's Hospital, United States

15:10  PL06.07: Diagnostic and Prognostic Evaluation of M-CSF and IL-34 Cytokines in Pleural Effusions from Mesothelioma Patients (Abstract ID: 613)
Thibaut Blondy, CRCINA, France

15:20  PL06.08: Question & Answer Period

15:30 - 16:00  Closing Remarks
Room: Confederation I - Level 4